Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5826750 | European Journal of Pharmacology | 2016 | 30 Pages |
Abstract
The therapeutic effectiveness of moracins as 2-arylbenzofuran derivatives against airway inflammation was examined. Moracin M, O, and R were isolated from the root barks of Morus alba, and they inhibited interleukin (IL)-6 production from IL-1β-treated lung epithelial cells (A549) at 101-00 μM. Among them, moracin M showed the strongest inhibitory effect (IC50=8.1 μM). Downregulation of IL-6 expression by moracin M was mediated by interrupting the c-Jun N-terminal kinase (JNK)/c-Jun pathway. Moracin derivatives inhibited inducible nitric oxide synthase (iNOS)-catalyzed NO production from lipopolysaccharide (LPS)-treated alveolar macrophages (MH-S) at 50-100 μM. In particular, moracin M inhibited NO production by downregulating iNOS. When orally administered, moracin M (20-60 mg/kg) showed comparable inhibitory action with dexamethasone (30 mg/kg) against LPS-induced lung inflammation, acute lung injury, in mice with that of dexamethasone (30 mg/kg). The action mechanism included interfering with the activation of nuclear transcription factor-κB in inflamed lungs. Therefore, it is concluded that moracin M inhibited airway inflammation in vitro and in vivo, and it has therapeutic potential for treating lung inflammatory disorders.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Ju Hee Lee, Hae Ju Ko, Eun-Rhan Woo, Sang Kook Lee, Bong Soo Moon, Chan Woo Lee, Suresh Mandava, Mallesham Samala, Jongkook Lee, Hyun Pyo Kim,